Theodore W. Laetsch - Concepedia

Author

Theodore W. Laetsch

The University of Texas Southwestern Medical Center ORCID

Also Known As

Amar, Salomon, Joris Nofiele, Ken Kazahaya, Ken Young, Noelle Williams, Rajiv Chopra, Salvatore La Rosa, T W Laetsch, T. Laetsch, T.W. Laetsch

368

Publications

17.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Children's Hospital of Philadelphia University of Pennsylvania Children's Hospital of Los Angeles Memorial Sloan Kettering Cancer Center

About

Theodore W. Laetsch is an author at The University of Texas Southwestern Medical Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	38	4.1K
2	Health Sciences	12	14	1.4K
3	Cell Biology	7	7	977
4	Engineering	3	3	172
5	Biomedical Engineering	1	1	47

Theodore W. Laetsch

104

Publications

16.2K

Citations

H-Index

Page 1

	Year	Citations
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner, New England Journal of Medicine	2018	5.4K
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, New England Journal of Medicine	2018	2.6K
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials David S. Hong, Steven G. DuBois, Shivaani Kummar, The Lancet Oncology Phase 1/2Surgical OncologyTumoral PathologyMedicineClinical Trials	2020	955
Comprehensive Analysis of Hypermutation in Human Cancer Brittany Campbell, Nicholas Light, David Fabrizio, Cell Somatic VariantCancer GenomicsComprehensive AnalysisMedicineCell Biology	2017	772
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study Theodore W. Laetsch, Steven G. DuBois, Leo Mascarenhas, The Lancet Oncology Tumoral PathologyMedicinePathologyPaediatric Solid TumoursCancer Genetics	2018	536
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma Marcelo C. Pasquini, Zhen‐Huan Hu, Kevin J. Curran, Blood Advances	2020	421
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, The Lancet Oncology Interim AnalysisLymphoid NeoplasiaSurgical OncologyMedicineMelanoma	2019	324
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial Theodore W. Laetsch, Shannon L. Maude, Susana Rives, Journal of Clinical Oncology	2022	314
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Vinod Pullarkat, Norman J. Lacayo, Elias Jabbour, Cancer Discovery	2021	270
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia Karen Thudium Mueller, Edward Waldron, Stephan A. Grupp, Clinical Cancer Research	2018	218

Page 1